-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$21.00154.85% Upside
Recent Analyst Forecasts and Stock Ratings
Iovance Biotherapeutics, Inc. Frequently Asked Questions
-
What analysts cover Iovance Biotherapeutics, Inc.?
Iovance Biotherapeutics, Inc. has been rated by research analysts at UBS, Stifel Nicolaus, Robert W. Baird, Piper Sandler, JMP Securities, Goldman Sachs in the past 90 days.